Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation
NCT05276726Phase 2Recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glecirasib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Aug 2022; status: recruiting.
02
Drugs
glecirasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05276726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276726.